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One sentence summary: 
Tenapanor reduces intestinal phosphate absorption through the reduction of passive paracellular 
phosphate flux; this effect is mediated exclusively via on-target sodium/hydrogen exchanger 
isoform 3 (NHE3) inhibition. 
  
 3 
 
ABSTRACT 
 
Hyperphosphatemia is common in patients with chronic kidney disease and is increasingly 
recognized to associate with poor clinical outcomes. Current management using dietary 
restriction and oral phosphate binders often proves inadequate. Tenapanor, a minimally-
absorbed, small-molecule inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), acts 
locally in the gastrointestinal tract to inhibit sodium absorption. Tenapanor also reduces 
intestinal phosphate absorption. Here we investigated the mechanism by which tenapanor 
reduces gastrointestinal phosphate uptake using in vivo studies in rodents and translational 
experiments on human intestinal stem cell-derived enteroid monolayers to model ion transport 
physiology. Tenapanor produces its effect predominantly through reduction of paracellular 
phosphate absorption. This occurs by modulating tight junctions, likely a result of the 
intracellular proton retention accompanying NHE3 inhibition, which increases trans-epithelial 
electrical resistance (TEER) and reduces permeability to phosphate. NHE3 knockout monolayers 
replicate the phosphate phenotype of tenapanor, and tenapanor did not affect TEER or phosphate 
flux in the absence of NHE3. Tenapanor also prevents active transcellular phosphate absorption 
compensation by decreasing the expression of NaPi2b, the major active intestinal phosphate 
transporter. In healthy human volunteers, tenapanor 15 mg twice daily for 4 days increased stool 
phosphorus and decreased urinary phosphorus excretion. In conclusion, tenapanor reduces 
intestinal phosphate absorption, predominantly through reduction of passive paracellular 
phosphate flux, quantitatively the most important mechanism of intestinal phosphate absorption. 
Tenapanor modulates tight junctions to increase TEER, thereby reducing paracellular 
permeability to phosphate; this effect is mediated exclusively via on-target NHE3 inhibition. 
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Main text: 
 
INTRODUCTION 
 
Patients with chronic kidney disease (CKD) are unable to maintain fluid and mineral balance. 
Reduced urinary excretion of phosphate due to renal insufficiency and the resultant 
hyperphosphatemia are associated with multiple complications, and addressing this imbalance is 
increasingly recognized as an important challenge in optimizing outcomes in patients with CKD 
(1). Intestinal phosphate absorption increases linearly with increasing dietary intake and does not 
saturate even at extremely high luminal phosphate concentrations (2-5). As a result, phosphate 
balance is principally maintained through the regulation of urinary phosphate excretion (6, 7). 
Reabsorption of phosphate in the renal tubule is modulated such that serum phosphate 
concentrations are maintained within a physiologic range despite considerable variations in daily 
phosphate intake. 
 
Hyperphosphatemia is a predictable consequence in patients with advanced CKD, especially in 
patients with end-stage renal disease (ESRD) receiving dialysis. This is, at least in part, due to 
sustained intestinal phosphate absorption in the face of impaired or absent urinary phosphate 
excretion, which cannot be fully compensated by standard dialysis regimens. This has important 
implications because Eelevated serum phosphate is associated with adverse outcomes in patients 
with CKD (8), including increased risk of all-cause mortality. Elevated serum phosphate levels 
in patients on hemodialysis (9-12) and in patients with CKD not on dialysis (9-12), associate 
with increased risk of all-cause mortality. In patients not on dialysis, elevated serum phosphate 
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has been associated with an increased risk of cardiovascular events (13), and CKD progression 
(14), while a recent study in a Chinese population reported that serum phosphate was anand is an 
independent risk factor for left ventricular hypertrophy (15). Furthermore, hyperphosphatemia in 
CKD is accompanied by increasing fibroblast growth factor 23 (FGF-23) levels concentration 
and secondary hyperparathyroidism, which contribute to metabolic bone disease, ectopic 
calcification, renal failure and progression of cardiovascular disease (16-18). 
 
Oral phosphate binders, together with dietary phosphate restriction, are the primary treatment 
approaches for patients with ESRD receiving dialysis (1, 19). Restricting dietary phosphate 
intake can reduce the severity of hyperphosphatemia and secondary hyperparathyroidism, 
although adherence is typically poor and this diet can result in nutritional deficiencies (20). Poor 
compliance has also been reported with oral phosphate binders (21). These agents are associated 
with numerous side effects, such as nausea, vomiting and constipation, and the large amount of 
binder required to capture dietary phosphate means that treatment is associated with a high pill 
burden for patients, which can further compromise compliance (22). 
 
Tenapanor is a first-in-class, minimally-absorbed, small-molecule inhibitor of the 
sodium/hydrogen exchanger isoform 3 (NHE3) that acts locally in the gastrointestinal tract. 
NHE3 was first identified as a drug target in CKD owing to its key role in intestinal sodium and 
fluid absorption (23). In both healthy rats and human volunteers, tenapanor increases stool 
sodium and reduces urinary sodium, with minimal systemic drug exposure (23). In 
nephrectomized rats fed a high-salt diet and exhibiting hypervolemia, cardiac hypertrophy and 
arterial stiffening, tenapanor reduced extracellular fluid volume, left ventricular hypertrophy, 
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albuminuria and blood pressure (23). In addition, tenapanor reduced intestinal absorption of 
radioactive phosphate, reduced urinary and serum phosphate, and both prevented ectopic 
calcification and lowered FGF-23 levels in a rat model of CKD (24). 
 
Dietary phosphate absorption occurs predominantly in the small intestine by at least two distinct 
pathways: transcellular and paracellular (25-27). Two families of sodium-dependent phosphate 
solute carrier (SLC) transporters responsible for the transport of phosphate into cells have been 
identified: the SLC34 (type II) and SLC20 (type III) families (25). The type II sodium-dependent 
phosphate transporter 2btransporter  (NaPi2b, SLC34A2)) accounts for more than 90% of 
sodium-dependent phosphate transport across the brush border membrane in the mouse ileum 
(32) and contributes most significantly to transcellular phosphate absorption in the intestine (28-
30). NaPi2b has a high affinity for phosphate (KM 10–100 µM); thus, it is saturated under most 
dietary conditions (3, 31). The type III sodium-dependent phosphate transporters (PiT) PiT1 
(SLC20A1) and PiT2 (SLC20A2) are also expressed in the intestine, although their contribution 
to intestinal phosphate absorption is limited as shown by the minimal transcellular sodium-
dependent phosphate uptake remaining in NaPi2b knockout (KO) mice (28, 29, 32, 33). 
Paracellular phosphate absorption through tight junction complexes is driven by the 
electrochemical phosphate gradient. An emerging body of literature demonstrates that tight 
junctions are dynamically regulated by signal transduction pathways, actively interact with the 
cytoskeleton, and can display some permeability specificity towards individual or selected ion 
groups (34, 35). In contrast to NaPi2b, paracellular phosphate absorption does not saturate, 
increases in a linear fashion with increasing phosphate concentration gradient and is bidirectional 
(2, 36). As luminal phosphate concentrations, even on standard diets, have been measured in the 
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millimolar range (3), far in excess of concentrations that saturate NaPi2b and higher than blood 
phosphate concentrationslevels, paracellular phosphate influx is probably the most quantitatively 
important overall mechanism of phosphate absorption under typical conditions of phosphate 
availability. In addition, increasing luminal phosphate concentration above levels that saturate 
NaPi2b saturation facilitates discrimination between these two transport pathways. 
 
Here we delineate the mechanism by which intestinal phosphate absorption is inhibited by 
tenapanor, investigating its effects on both passive paracellular phosphate absorption and 
NaPi2b-mediated phosphate transport. Phosphate absorption has been observed along the entire 
length of the small intestine; however, species-specific regional variations have been described. 
A direct comparison of segment-specific phosphate absorption in rats and mice, using the in vivo 
loop technique, revealed it to be quantitatively highest in the duodenum of the rat and in the 
ileum of the mouse (37). Classic physiology experiments in humans, using the triple lumen 
catheter perfusion technique in vivo, showed substantial and non-saturating phosphate absorption 
across both the proximal and distal small intestine, although quantitatively higher proximally: 
more consistent with observations in rats than in mice (2). Therefore, to comprehensively 
investigate the effect of NHE3 inhibition on phosphate absorption along the length of the small 
intestine, we used enteroid monolayer cultures (38) derived from human distal duodenum and 
ileum to capture mechanisms of both proximal and distal absorption in humans and 
complemented this with experiments in the jejunum of mouse and rat. Mouse ileum, a segment 
where NaPi2b is highly expressed and plays a dominant role in phosphate absorption, was used 
to specifically assess the role of NaPi2b in the phosphate-lowering mechanism of tenapanor. We 
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also report the effects of tenapanor on intestinal phosphate absorption in healthy human 
volunteers.  
 9 
 
RESULTS  
 
Effects of tenapanor on passive paracellular phosphate absorption  
Tenapanor reduces phosphate absorption in vivo 
In a rat intestinal loop model, tenapanor reduced radioactive phosphate absorption in the 
jejunum, a key site of intestinal phosphate absorption in rats (37), versus vehicle to an amount 
similar level toto that observed in sodium-free conditions (Fig. 1A).  
 
The effects of acute increases in luminal phosphate were examined in rats by increasing the 
phosphate concentration in an oral bolus, with sodium levels matched by the addition of sodium 
chloride. Proportionate increases in urinary phosphate excretion, an indirect marker of intestinal 
phosphate absorption, were seen with increasing phosphate concentration (Fig. 1B). This linear 
concentration-dependence of absorption and failure to saturate, even at high concentrations of 
luminal phosphate, is characteristic of passive paracellular absorption, not NaPi2b-mediated 
phosphate absorption (which saturates at low luminal phosphate concentrations). Tenapanor 
reduced phosphate absorption across all phosphate concentrationslevels, significantly decreasing 
urinary phosphate excretion even at high phosphate concentrations (Fig. 1B), suggesting that 
tenapanor reduces paracellular phosphate absorption. Increasing concentrations of phosphate in 
the bolus had minimal effect on urinary sodium excretion, and tenapanor significantly reduced 
urinary sodium excretion to a similar extent across all phosphate concentrations compared with 
vehicle (tenapanor vs vehicle, 0.15 M phosphate bolus: 8 ± 2 vs 26 ± 3 mg/4 hours, P < 0.0001; 
0.5 M phosphate bolus: 8 ± 0.3 vs 29 ± 1 mg/4 hours, P < 0.0001; 1.5 M phosphate bolus: 4 ± 1 
vs 39 ± 1 mg/4 hours, P < 0.0001).  
 10 
 
 
The effects of tenapanor during chronic changes in dietary phosphate intake in rats were 
investigated. Increases in dietary phosphate content produced significant, linear and non-
saturating increases in urinary phosphate excretion at baseline, consistent with passive 
paracellular absorption (Fig. 1C). Tenapanor significantly reduced urinary phosphate excretion 
after 4 days of administration, suggesting the inhibition of a constant fraction of intestinal 
phosphate absorption despite increasing dietary phosphate content, indicative of a reduction in 
paracellular, not transcellular, absorption (Fig. 1C). Significant reductions in urinary sodium 
excretion were also observed with tenapanor relative to vehicle, which were constant across 
varying dietary phosphate levels (tenapanor vs vehicle, 0.3% phosphate: 6 ± 1 vs 17 ± 2 mg/day, 
P < 0.0001; 0.6% phosphate: 3 ± 1 vs 19 ± 2 mg/day, P < 0.0001; 1.2% phosphate: 6 ± 2 vs 16 ± 
2 mg/day, P < 0.001). 
 
Paracellular phosphate absorption could be reduced by at least two potential mechanisms as a 
result of NHE3 inhibition: (i) a general decrease in paracellular water flux and diffusional 
driving force caused by luminal sodium and water retention (this would be accompanied by 
minimal change or a decrease in luminal phosphate concentration) and/or (ii) a decrease in 
paracellular permeability to phosphate through the tight junction (this would be accompanied by 
an increase in luminal phosphate concentration). To investigate this, an enteropooling study was 
performed in healthy rats trained to eat a high-phosphate meal (1.2%), with both ion mass and 
ion concentration then being measured in the cecum at defined time points. The small intestine is 
the primary site of phosphate absorption, therefore the concentration of phosphate and other ions 
in the cecum reflects the amount not absorbed in the small intestine.  
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In this enteropooling model, tenapanor significantly reduced urinary phosphate and sodium 
excretion following the high phosphate meal, reflecting a significant decrease in overall 
intestinal phosphate and sodium absorption (Fig. 1D). Tenapanor treatment resulted in 
significantly increased delivery of both sodium (Fig. 1E) and phosphate (Fig. 1F) to the cecum, 
confirming decreased absorption of these ions in the small intestine. Following vehicle treatment, 
very little phosphate was delivered to the cecum, even in the face of a high-phosphate load, 
indicating a high capacity for phosphate absorption in the small intestine (Fig. 1F). Luminal 
sodium retention observed with tenapanor treatment was accompanied by significantly increased 
luminal water volume (Fig. 1G) and luminal sodium concentration (Fig. 1H). In addition, the 
inhibition of intestinal phosphate absorption that resulted from tenapanor treatment was 
accompanied by an significant increase in luminal phosphate concentration (Fig. 1I). This 
suggests that tenapanor decreases paracellular permeability to phosphate rather than reducing the 
driving force through a dilutional effect on luminal phosphate concentration. Reduced water 
absorption may also contribute to decreased phosphate absorption via decreased paracellular 
solvent drag. 
 
Potassium is reported to be exclusively absorbed in the small intestine via passive paracellular 
flux (39). Therefore, we also measured luminal potassium concentration in the enteropooling 
model to evaluate the in vivo ion selectivity of tenapanor. In contrast to phosphate, luminal 
potassium concentration was significantly decreased by tenapanor (Fig. 1J), consistent with 
greater solute dilution secondary to luminal water retention because of decreased transcellular 
sodium absorption, relative to any reduction in paracellular potassium flux. Combined, these 
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findings illustrate the in vivo selectivity of tenapanor for phosphate relative to potassium, another 
ion absorbed by the paracellular route. 
 
Further evaluation of the ionic specificity of tenapanor included the measurement of cecal 
chloride, calcium and magnesium concentrations in the enteropooling model. Cecal chloride 
concentrations were low, indicative of high-capacity chloride absorption in the small intestine 
against the prevailing chemical gradient opposed by high plasma chloride concentrations (98– 
106 mM); consistent with a prominent role of active transcellular chloride transport (Fig. 1K). 
Tenapanor increased the luminal chloride concentration compared with vehicle control; however, 
the maximal increase in chloride concentration was modest (1.6-fold) compared with the 
maximal tenapanor induced increases in phosphate concentration (5.7-fold), demonstrating a 
preferential effect of tenapanor on phosphate relative to chloride. Given the low cecal 
concentration of chloride relative to plasma chloride concentrations, which would be insufficient 
to support paracellular chloride absorption, the modest increase in cecal chloride observed with 
tenapanor treatment is likely the result of a disruption in electroneutral transcellular sodium 
chloride absorption, which would be a direct result of NHE3 inhibition, rather than reduced 
paracellular chloride absorption. 
 
The concentrations of divalent cations calcium (Fig. 1L) and magnesium (Fig. 1M) in the cecum 
were also low, comparable to their respective plasma concentrations and indicating efficient 
small intestinal absorption of these cations. Tenapanor did not significantly (P > 0.05) affect 
cecal concentrations of calcium or magnesium, demonstrating specificity towards inhibition of 
phosphate absorption relative to divalent cation absorption. 
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Tenapanor inhibits paracellular phosphate flux in a cellular model of the intestinal epithelial 
monolayer across a wide range of phosphate concentrations 
We used a novel system of culturing intestinal epithelial stem cells from human or mouse 
gastrointestinal biopsies as monolayers, which allows the transport of ions across the intestinal 
epithelium to be monitored (38). The enteroid monolayer contains the diversity of intestinal 
epithelial cell lineages, models the specific gene expression patterns of each individual intestinal 
segment, expresses the appropriate endogenous ion transporters (for example, NHE3 and 
NaPi2b) in a segment-specific manner, polarizes to form tight junctions with segment-specific 
expression of claudins and other tight junction proteins, and generates the expected negative 
luminal electrical potential observed in vivo. The differentiated enteroid monolayer therefore 
enables the study of transcellular and paracellular phosphate absorption. 
 
NHE3 is highly expressed along the length of the gastrointestinal tract (40) and is endogenously 
expressed in each segment of the intestinal monolayer model, as shown in representative images 
from the ileum (Fig. S1A). Most cells in the monolayer are absorptive cells, similar to in vivo, 
and are polarized, expressing NHE3 only at the apical surface (Fig. S1B). The enteroid 
monolayer therefore provides a model system to study the role of native NHE3 in intestinal 
phosphate absorption. Proton secretion coupled to sodium absorption by NHE3 results in 
acidification of the apical media of the monolayer. This was inhibited by tenapanor, monitored 
by the color change of pH-sensitive phenol red in the apical media (Fig. S1C). Concentration–
response studies measuring apical pH using 2',7'-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein, acetoxymethyl ester (BCECF-AM) dye, where a decrease in the 
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fluorescence emission ratio (from excitation at 490/440) reflects a decrease in pH, showed that 
tenapanor inhibited apical acid secretion by NHE3 with a half-maximal inhibitory concentration 
(IC50) of 2 nM and 6 nM in human and mouse ileum monolayers, respectively (Fig. S1D). This is 
consistent with the potency of tenapanor against NHE3 in primary target assays (23). In human 
ileum and duodenum cell monolayer cultures, tenapanor caused a concentration-dependent 
inhibition of the NHE3-mediated recovery of intracellular pH (pHi) following acid loading (IC50: 
ileum, 13 nM; duodenum, 9 nM) (Fig. S1E, F). Based on the potency of NHE3 inhibition in the 
intestinal monolayer culture system, subsequent experiments investigating effects on phosphate 
absorption used a tenapanor concentration of 1 µM to ensure complete NHE3 inhibition. 
 
Assessment of apical-to-basolateral phosphate flux in duodenum cell monolayer cultures derived 
from two healthy human donors showed significant (P < 0.0001), linear (R2 = 0.989 for donor A, 
R2 = 0.998 for donor B) and non-saturating increases in phosphate flux with increasing apical 
phosphate concentrations (1–30 mM) (Fig. 2A). Under these conditions, NaPi2b would be 
saturated even at the lowest phosphate concentration. This indicates that passive paracellular 
absorption is the primary route of phosphate absorption in the human duodenum model, 
consistent with the absence of phosphate transporter expression in the duodenum epithelial cell 
monolayer culture, and the lack of effect of a NaPi2b inhibitor (41) on duodenal phosphate 
absorption in the monolayer (Fig. S1G).  
 
The effects of apical tenapanor administration on phosphate flux were first evaluated by 
measuring changes in basolateral phosphate concentration following a 4-hour treatment period in 
duodenum cell monolayer cultures. The initial apical phosphate concentration was varied from 
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1 mM to 30 mM while the initial basolateral phosphate concentration was fixed at 0 mM. 
Phosphate absorption was strongly dependent on the apical-basolateral phosphate concentration 
gradient, and basolateral phosphate concentration (Fig. 2B) and phosphate flux (Fig. 2C) were 
significantly lower with tenapanor treatment across the range of phosphate concentrations. 
Tenapanor also increased trans-epithelial electrical resistance (TEER) following a 4-hour 
incubation in human duodenum monolayer cultures compared with vehicle (Fig. 2D), consistent 
with a decrease in paracellular permeability. Treatment with tenapanor did not affect the 
potential difference (−5.3 ± 0.26 mV relative to basolateral) across the monolayer compared with 
vehicle control (−5.5 ± 0.3 mV), importantly indicating the electrical driving force for phosphate 
flux is not significantly affected by tenapanor. 
 
The effects of tenapanor on phosphate absorption in the human duodenum cell monolayers were 
further evaluated following overnight treatment to incorporate measurable apical-to-basolateral 
water flux across a range of initial apical phosphate concentrations (1–30 mM), with the initial 
basolateral phosphate concentration set at 1 mM. Overnight treatment with tenapanor inhibited 
phosphate absorption across the range of phosphate concentrations, indicated by a significantly 
higher retention of phosphate in the apical compartment compared with vehicle (Fig. 2E). 
Consistent with decreased phosphate permeability, the retention of phosphate in the apical 
chamber produced by tenapanor was accompanied by significantly higher apical phosphate 
concentrations compared with vehicle (Fig. 2F). Conversely, basolateral phosphate 
concentrations were significantly reduced with tenapanor exposure (Fig. 2G). In addition, NHE3 
inhibition by tenapanor decreased apical-to-basolateral water absorption (Fig. 2H), as a result of 
decreased transcellular sodium flux. Similar results were observed in human ileum monolayers 
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(Fig. S2), showing that tenapanor also inhibits phosphate absorption in the distal small intestine 
of humans.  
 
An additional and identifying characteristic of paracellular transport is bidirectional flux, based 
on the prevailing electrochemical gradient. Consistent with phosphate moving across human 
duodenum monolayer cultures through the paracellular pathway, we demonstrated basolateral-to-
apical phosphate flux that was linearly dependent on the trans-epithelial phosphate concentration 
gradient, which is non-saturating through a 10 mM phosphate gradient (Fig. 2I). The magnitude 
of phosphate flux at a given phosphate concentration gradient was similar in both directions, 
although appeared to be slightly reduced in the basolateral-to-apical direction, which is likely a 
result of the unfavorable electrical gradient to reverse phosphate flux generated by the negative 
luminal potential established across the monolayer (−5.5 ± 0.3 mV relative to basolateral). 
Apically applied tenapanor effectively reduced basolateral-to-apical phosphate flux at all 
phosphate concentrations tested, comparable to the effect on apical-to-basolateral phosphate 
absorption (Fig. 2I). Combined, these results suggest that tenapanor inhibits phosphate flux by 
decreasing paracellular permeability, consistent with the in vivo enteropooling results. 
 
Tenapanor increases TEER when there is a favorable gradient for NHE3-mediated proton efflux  
The effect of tenapanor on paracellular permeability was further evaluated by measuring TEER 
in the intestinal epithelial cell monolayer culture system. Proton secretion by NHE3 gradually 
acidifies the apical media in the monolayer cultures, which results in an unfavorable proton 
gradient for NHE3-mediated transport. The reduction in NHE3-mediated proton efflux in the 
setting of an elevated luminal proton concentration has been described in the renal tubule (42). 
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Thus, in order to initiate phosphate absorption experiments, the acidified cell culture media was 
replaced with media of a defined starting phosphate concentration and a neutral apical pH.  
 
The change to neutral apical media immediately restored the proton gradient, thereby driving 
NHE3-mediated proton efflux. This resulted in a large and sustained reduction in TEER from 
baseline levels in the monolayer cultures from both the duodenum (Fig. 3A) and ileum (Fig. 3B), 
which was completely blocked by tenapanor (Fig. 3A, B). This shows that TEER is elevated 
when NHE3 is inhibited by tenapanor or when NHE3-mediated proton efflux is reduced by an 
unfavorable proton gradient, both of which result in intracellular proton accumulation. 
 
Luminal pH modulates pHi, NHE3-mediated proton efflux, TEER and phosphate absorption 
The impact of both luminal pH and tenapanor on TEER were further investigated using the cell 
monolayer culture system. In human duodenum monolayers, apical pH had a strong influence on 
TEER. Replacing the old acidified apical media (pH 6.0) with fresh media produced similar 
reductions in TEER from baseline under neutral (pH 7.0) and alkaline (pH 8.0) conditions, but 
caused an increase in TEER when acidic media (pH 5.5) was introduced (Fig. 3C). Fresh media, 
matched to the old apical media (pH 6.0), had no effect on TEER (Fig. 3C). Compared with the 
TEER of the equivalent pH control, tenapanor increased TEER at neutral and alkaline luminal 
pH, but not under acidic conditions, when NHE3-mediated proton efflux was unfavorable and 
TEER already high (Fig. 3D). 
 
Further studies, using the pH-sensitive dye BCECF-AM, showed that the rate and magnitude of 
recovery of pHi following acid loading (a direct measure of NHE3-mediated proton efflux in the 
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enterocyte) were reduced with decreasing luminal pH in both duodenum and ileum monolayer 
cultures (Fig. 3E, F). Tenapanor reduced pHi recovery at each of the luminal pH values tested 
(pH 6, 7 and 8; Fig. 3E, F). Although NHE3-mediated proton efflux was reduced at pH 6.0 
compared with pH 7.0, the potency of tenapanor in inhibiting NHE3 was unaffected by 
extracellular pH (IC50: pH 6.0, 10 nM; pH 7.0, 9.5 nM) (Fig. 3G).  
 
In human ileum monolayer cultures, changes in luminal pH were rapidly accompanied by 
changes in pHi, monitored using BCECF-AM dye, and TEER. Both occurred within 1 minute 
after manipulation of the apical media pH (Fig. 3H–J). A rapid reduction in pHi was observed at 
luminal pH 6.0. A higher pHi was seen when neutral (pH 7.0) or alkaline (pH 8.0) media was 
added, although there was little difference between pH 7.0 and 8.0 (Fig. 3H), similar to the 
effects of luminal pH on TEER. At neutral apical pH (when NHE3 is effectively effluxing 
protons), tenapanor significantly reduced pHi, to a similar extent observed with pH 6.0 apical 
media, with effects observed within 1 minute (the first time point technically possible to 
measure) of initiating tenapanor treatment (Fig. 3I). The effects of luminal pH and tenapanor on 
changes in TEER were similarly rapid. In monolayer cultures mounted in Ussing chambers, 
which permit dynamic and continuous TEER measurements, tenapanor application resulted in a 
near immediate increase in TEER compared with vehicle control (Fig. 3J). Therefore, inhibition 
of NHE3, by tenapanor or decreased NHE3-mediated proton efflux as a result of acidic luminal 
media, results in a rapid (< 1 minute) reduction in pHi and a correspondingly rapid increase in 
TEER. 
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The effects of luminal pH on phosphate absorption were also evaluated using the ileum 
monolayer culture system. Starting with initial apical phosphate concentrations of 10 mM or 
30 mM and an initial basolateral phosphate concentration of 0 mM, phosphate flux was 
measured during overnight exposure to acidic (pH 6.0), neutral (pH 7.0) and alkaline (pH 8.0) 
apical media, with and without tenapanor. There was a strong, positive and significant 
relationship between apical pH and phosphate flux at initial apical phosphate concentrations of 
both 10 mM (R2 = 0.94, P < 0.0001) and 30 mM (R2 = 0.92, P < 0.0001) (Fig. 4A). Tenapanor 
reduced phosphate absorption across the pH range 6.0–8.0, with the reduction in phosphate flux 
being significantly higher at pH 7.0 and pH 8.0 compared with pH 6.0, but no difference between 
pH 7.0 and pH 8.0 (Fig. 4B).  
 
To confirm that the results obtained in enteroid monolayers translate to intestinal tissue, 
phosphate flux measurements, by radioactive tracer, and paracellular phosphate permeability 
measurements, by biionic dilution potential, were made in ex vivo mouse jejunum mounted in 
Ussing chambers at pH 6.0 and 8.0. Consistent with the human duodenum monolayer results, 
both phosphate flux (Fig. 4C) and permeability (Fig. 4D) were increased at pH 8.0 compared 
with pH 6.0. Combined, these results suggest increased phosphate permeability at pH 8.0 in both 
human duodenum monolayer cultures and mouse jejunum; conditions where the predominant 
phosphate species is HPO4
2−. In addition to preferential paracellular permeability to the HPO4
2− 
species, the electrical gradient imposed by the negative lumen potential in vivo generates a 
greater driving force for absorption of the HPO4
2− species, relative to the H2PO4
− species that is 
more abundant at pH 6.0. Thus, the neutral-to-alkaline pH range encountered in the distal small 
intestine provides optimal conditions for paracellular phosphate absorption. 
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Biophysical assessment of paracellular permeability using dilution and biionic potential 
measurements 
Paracellular sodium and chloride permeability and paracellular phosphate permeability were 
determined from sodium chloride dilution potentials and phosphate biionic potentials, 
respectively, in both human duodenum monolayer cultures and mouse jejunum ex vivo mounted 
in Ussing chambers at pH 8.0.  
 
In human duodenum monolayer cultures, tenapanor significantly increased TEER (Fig. 5A), 
accompanied by a corresponding decrease in permeability to sodium (Fig. 5B) and chloride (Fig. 
5C), such that sodium-to-chloride permeability (Fig. 5D) was unchanged, and a significant 
decrease in phosphate permeability (Fig. 5E), confirming decreased paracellular permeability to 
phosphate. A consistent effect of tenapanor on paracellular permeability was observed in mouse 
jejunum ex vivo (Fig. 5F–J).  
 
The preferential inhibition of intestinal phosphate (and sodium) absorption by tenapanor in vivo, 
relative to other ions including chloride, is not readily reflected in these direct biophysical 
measurements of paracellular permeability. It is important to recognize that measurements of 
paracellular ion permeability made via in vitro dilution potential measurements are not 
equivalent to in vivo paracellular ion flux, which is the integrated result of paracellular 
permeability and the prevailing electrochemical gradient. Sodium and chloride permeability was 
assessed in the Ussing chamber by acutely imposing an approximately 100 mM chemical 
gradient to enable dilution potentials to be measured; a gradient unlikely to be achieved in vivo 
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due to the high plasma concentration of both sodium (135–145 mM) and chloride (96–106 mM) 
opposing paracellular absorption from the lumen. To better assess the actual driving force for 
various ions in vivo, we measured ion concentrations in both the proximal and distal small 
intestine at defined time points in untreated, healthy rats after ingestion of a high-phosphate 
(1.2%) meal, which would be typical of processed food. Peak luminal intestinal sodium 
concentrations were observed in the distal small intestine, and approximated normal plasma 
sodium concentrationslevels (Fig. 5K). Combined with the negative luminal potential, the 
electrochemical gradient did not therefore provide a strong impetus for paracellular sodium 
absorption; in fact, there could potentially be secretion. Luminal chloride concentrations were 
maximal in the proximal small intestine, but still below normal plasma chloride concentrations, 
and decreased significantly in the distal small intestine (Fig. 5L). Even with a favorable 
electrical gradient for absorption of a negative anion, paracellular chloride absorption would not 
be supported in this concentration range. The absence of the requisite electrochemical gradients 
to drive substantial paracellular sodium and chloride flux in vivo suggests a prominent role for 
transcellular absorption of these ions, consistent with the high expression of ion exchangers for 
both sodium (NHE3) and chloride (SLC26A3 [DRA] and SLC26A6 [PAT1/CFEX]) in the small 
intestine (43). 
 
In contrast, low plasma phosphate concentrationslevels, high luminal phosphate concentrations 
and a negative luminal potential difference across the intestinal epithelium provides a strong 
electrochemical gradient for luminal phosphate absorption (Fig. 5M). Importantly, the electrical 
gradient across the intestinal epithelium is lumen negative, and luminal phosphate is 
predominantly a divalent anion, magnifying the driving force for paracellular phosphate four-
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fold relative to chloride. Combined with the absence of a low affinity, high capacity transcellular 
phosphate transporter, at high luminal concentrations, phosphate appears to be dependent on 
paracellular flux for absorption. The reliance of phosphate on paracellular absorption and the 
strength of the driving force for phosphate flux likely explain the preferential effect of tenapanor 
on phosphate absorption. 
 
NHE3-independent changes in pHi modulate TEER 
The cell monolayer culture system was used to evaluate the effects on TEER of intracellular 
acidification occurring independent of changes in NHE3 activity. The ionophore nigericin 
reduced pHi compared with control (Fig. S3A), and produced a similar increase in TEER relative 
to control as was observed with tenapanor (Fig. S3B). Similarly, the compounds N5,N6-bis(2-
Fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine (BAM15) and mesoxalonitrile 4-
trifluoromethoxyphenylhydrazone (FCCP), which decrease pHi by uncoupling oxidative 
phosphorylation in the mitochondria (Fig. S3C), increased TEER compared with control (Fig. 
S3D). Moreover, neither nigericin, BAM15 nor FCCP inhibited NHE3 activity in enterocytes, as 
assessed by pHi recovery following acid loading. These results show that pHi is a direct 
regulator of TEER, independent of NHE3 activity.  
 
NHE3 KO monolayers phenocopy tenapanor, and tenapanor does not inhibit paracellular 
phosphate absorption in the absence of NHE3 
CRISPR/Cas9-mediated gene editing was used to produce human ileum epithelial stem cell 
clones with nucleotide insertions/deletions (Fig. 6A) resulting in a complete loss of NHE3 
expression and function, confirmed by NHE3 western blotting (Fig. 6B), visual loss of apical 
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media acidification in monolayer cultures (Fig. 6C) and reduced recovery from intracellular 
acidification following acid loading (Fig. 6D, E). NHE3 KO monolayers were otherwise 
morphologically indistinguishable from control monolayers and had similar baseline TEER 
values. 
 
In monolayer culture studies, the NHE3 KO clones showed the same phenotype as tenapanor-
treated cells. Following overnight incubation, NHE3 KO monolayers showed reduced absorption 
of water (Fig. 6F), sodium (Fig. 6G) and phosphate (Fig. 6H), as indicated by their apical 
retention, compared with control monolayers (Cas9 cells with non-targeting control guide RNA). 
In addition, NHE3 KO cells had reduced apical proton secretion and increased apical media pH 
compared with the control monolayers (Fig. 6I). With the restoration of neutral apical media and 
hence NHE3-mediated proton secretion in control cells, there was a marked decrease in TEER 
from baseline in control cultures (Fig. 6J). However, no change in TEER was observed in the 
NHE3 KO cells.  
 
Consistent with earlier results, tenapanor significantly inhibited apical-to-basolateral phosphate 
absorption in control cells (Fig. 6K); this was accompanied by an increased apical phosphate 
concentration compared with control (Fig. 6L). By contrast, tenapanor had little effect on 
phosphate absorption (Fig. 6K) or apical phosphate concentration (Fig. 6L) in NHE3 KO cells. 
Similarly, tenapanor administration increased TEER relative to vehicle only in control cells and 
had no effect on TEER in NHE3 KO cells (Fig. 6M). These findings indicate that the effects of 
tenapanor on phosphate absorption, paracellular phosphate permeability and TEER are mediated 
via on-target NHE3 inhibition.  
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CRISPR/Cas9-mediated NHE3 deletion in human duodenum monolayers (Fig. S4A, B) also 
replicated the phenotype of tenapanor in reducing apical media acidification (Fig. S4C), delaying 
recovery from intracellular acidification (Fig. S4D), increasing TEER (Fig. S4E, F) and 
reducing apical-to-basolateral sodium and phosphate absorption (Fig. S4G, H) compared with 
control cells. Tenapanor had no effect on TEER or apical-to-basolateral sodium and phosphate 
absorption in NHE3 KO duodenum monolayers (Fig. S4F–H). This further confirms that the 
effects of tenapanor on paracellular phosphate permeability, absorption and TEER are mediated 
via the action of tenapanor on NHE3. 
 
 
Further characterization of tenapanor including effect on 24-hour urinary ion excretion 
and transcellular phosphate transporter NaPi2b  
Effects of long-term administration of tenapanor on phosphate, sodium, chloride and potassium 
in vivo 
To characterize the effects of tenapanor further, including effects on the renal handling of 
sodium and phosphate, on phosphaturic hormones and on NaPi2b expression, healthy rats were 
dosed for 14 days with tenapanor. Tenapanor decreased urinary sodium (Fig. S5A) and 
phosphate (Fig. S5B) excretion but had no effect on urinary chloride (Fig. S5C) or potassium 
(Fig. S5D) excretion (normalized to dietary intake of each ion to correct for any daily 
fluctuations in food intake). In healthy rats, tenapanor did not affect plasma sodium or phosphate 
concentration (Fig. S5E), because renal clearances of both phosphate and sodium were 
appropriately decreased relative to control (Fig. S5F). Furthermore, tenapanor had minimal 
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effect on phosphate-regulating hormones (FGF-23, parathyroid hormone and vitamin D) in 
healthy animals receiving a regular phosphate diet (Fig. S5G, although tenapanor does 
significantly reduce FGF-23 and parathyroid hormone levels in animals with CKD (24)) or in 
those on a high-phosphate diet (data not shown).  
 
The effect of tenapanor on urinary sodium excretion was maximal on the first few days of 
treatment (Fig. S5A), and remained significantly reduced compared with vehicle for the duration 
of treatment. However, the reduction was attenuated in magnitude from treatment day 5, 
suggesting the engagement of a compensatory response to inhibition of intestinal sodium 
absorption. To investigate this, the expression of transcellular sodium transporters was measured 
by RNA sequencing (RNA-seq) along the length of the gastrointestinal tract. In tenapanor-
treated rats, NHE3 expression was significantly increased in the jejunum, ileum and proximal 
colon (Fig. S5H) and epithelial sodium channel gamma subunit (ENaCγ) expression was 
increased in the distal colon (Fig. S5I), indicating an attempt to increase intestinal sodium 
absorption. Since NHE3 will remain inhibited in the continued presence of tenapanor, it is likely 
increased colonic sodium absorption via upregulated ENaC is responsible for the attenuation of 
the reduction of urinary sodium excretion over time. To assess whether the lack of effect of 
tenapanor on urinary chloride excretion (Fig. S5C) required a similar compensatory response as 
observed for sodium, we also measured the expression of the most prominent chloride 
exchangers and transporters along the length of the gastrointestinal tract. The expression of 
chloride exchangers DRA (SLC26A3 (Fig. S5J),  and PAT1/CFEX (SLC26A6 (Fig. S5K) and 
chloride channel CFTR (Fig. S5L), were unchanged by tenapanor treatment. The maintenance of 
normal chloride balance in the absence of a transcriptional response to upregulate chloride 
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exchangers and transporters, in contrast to the effect on sodium transporters and channels, is 
consistent with minimal impact of tenapanor on intestinal chloride absorption. 
 
Tenapanor produces a modest decrease in NaPi2b expression 
The active phosphate transporter NaPi2b showed a modest (approximately 30%) but statistically 
significant (P < 0.01) decrease in mRNA expression in the distal jejunum and ileum following 14 
days of tenapanor treatment (Fig. 7A). In addition, immunohistochemistry using an antibody 
specific to NaPi2b showed a modest decrease in staining intensity in the jejunum following 
tenapanor treatment in a separate study (Fig. 7B). Transcellular phosphate transport was assessed 
using intestinal brush border membrane vesicles (BBMV) isolated following in vivo tenapanor 
administration in rats. This transport system is predominantly driven by NaPi2b. Tenapanor had 
little effect on transcellular phosphate uptake, including sodium-dependent phosphate absorption, 
in either duodenum or jejunum BBMVs compared with control (Fig. S6A, B), indicating 
minimal functional effect of tenapanor on NaPi2b-mediated phosphate absorption. Combined, 
these findings indicate that NaPi2b expression and consequently transcellular phosphate 
absorption do not increase to compensate for the decrease in passive paracellular phosphate 
absorption produced by tenapanor. In addition, tenapanor did not affect sodium-dependent 
glucose absorption in duodenum BBMVs (Fig. S6C).  
 
Tenapanor has minimal effect on NaPi2b activity in cellular and in vivo studies 
The effects of tenapanor on NaPi2b function were also assessed in monolayer cell cultures from 
the mouse ileum; these had high NaPi2b expression (55 560 counts as assessed by RNA-seq), 
which were similar to those observed in the mouse ileum in vivo (30 545 counts).  
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In mouse ileum monolayers, evaluation of phosphate absorption at increasing initial apical 
phosphate concentrations (1–5 mM) with a fixed initial basolateral phosphate concentration 
(1 mM) showed similar decreases in apical phosphate concentration following overnight 
incubation, irrespective of initial starting concentration (Fig. 7C); phosphate was transported in 
the absence of a concentration gradient, consistent with transcellular flux. Final basolateral 
phosphate concentration was also similar despite the different starting apical phosphate 
concentrations (Fig. 7C), showing that phosphate absorption in the mouse ileum was minimally 
affected by the phosphate concentration gradient. This is a typical characteristic of high-affinity 
active transport that saturates at low phosphate concentrations of less than 1 mM, and is 
consistent with the known characteristics of NaPi2b.  
 
In the absence of an apical-to-basolateral phosphate gradient, incubation of mouse ileum 
monolayers with NTX-9066 (41), a potent NaPi2b inhibitor, at 1 µM for 4 hours, 2 days or 3 
days completely blocked apical-to-basolateral phosphate absorption at all time points (Fig. 7D). 
By contrast, phosphate absorption in the mouse ileum monolayer was unaffected by tenapanor 
(1 µM) compared with vehicle at all time points measured (Fig. 7D). These findings indicate that 
phosphate absorption in the mouse ileum monolayer cultures is active, saturates at low luminal 
phosphate concentrations imparting a relatively low capacity of phosphate absorption, and is 
mediated exclusively by NaPi2b; they also indicate that tenapanor does not affect NaPi2b-
mediated ileal phosphate absorption.  
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The effects of tenapanor were also evaluated in the in vivo loop model in the ileum of wild-type 
and NaPi2b KO mice (28). Almost all (90%) phosphate absorption in the mouse ileum was 
mediated by NaPi2b (Fig. 7E), similar to the mouse ileum monolayer (Fig. 7D). Tenapanor 
produced a small, non-significant (P > 0.05) decrease in phosphate absorption in both wild-type 
and NaPi2b KO mouse ileum (Fig. 7E). This further suggests that the phosphate-lowering effect 
of tenapanor is not dependent on NaPi2b. 
 
 
How tenapanor modulates paracellular phosphate permeabilityEffects of tenapanor on 
tight junction protein localization and trafficking 
In order to clarify the mechanism by which tenapanor modulates TEER in human monolayer 
cultures, we investigated the potential involvement of key signaling pathways and second 
messengers. In Caco2 cells, NHE3 activity, via myosin II regulatory light-chain (MLC) 
phosphorylation, reduced TEER via the actin cytoskeleton (48). In our human duodenum 
monolayer with native NHE3 expression, however, phosphorylation of MLC was not reduced by 
tenapanor, and an MLC kinase inhibitor, ML-7 (10 µM), had no effect on baseline TEER or 
tenapanor-induced TEER changes (data not shown). A broad phospho-array panel failed to show 
clear activation of any classic signaling pathways. We observed that the acid-sensitive kinase 
Pyk2 was transiently phosphorylated by reduction in luminal pH with subsequent SRC 
phosphorylation, but not by tenapanor treatment. Furthermore, an extensive panel of kinase 
inhibitors did not convincingly affect the ability of tenapanor to modulate TEER. Tenapanor 
does not activate key GPCR second messengers, including intracellular calcium, cAMP or 
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cGMP, and established inhibitors of GPCR signaling again did not influence the effect of 
tenapanor on TEER (data not shown). [A1] 
Finally, dDirect assessment of tight junction protein localization was performed by confocal 
microscopy in the presence or absence of tenapanor treatment in the human ileum monolayer 
model. There was no obvious change in the localization of tight junction proteins zona 
occludens-1, occludin, claudin 7 or claudin 3, or NHE3 (not shown), assessed following 30, 60 
or 120 minutes of tenapanor treatment (Fig. S7A–C). As the panel of validated tight junction 
protein antibodies for immunocytochemistry is limited, we further evaluated the involvement of 
protein trafficking in the tenapanor-induced TEER effect to determine whether protein 
trafficking from the tight junction is responsible. Pitstop2 and dynasore (inhibitors of clathrin 
and dynamin, respectively) were shown to inhibit endocytosis effectively in the ileum monolayer 
by preventing carbachol-induced NHE3 internalization (Fig. S7D). However, neither pitstop2 
(Fig. S7E) nor dynasore (Fig. S7F) blocked tenapanor-induced increases in TEER compared 
with control, indicating that endocytosis is not required for this effect of tenapanor.  
 
The rapid increase in TEER without obvious signaling pathway or tight junction protein 
trafficking involvement might be consistent with the inhibition of NHE3 by tenapanor producing 
a pH-sensitive conformational change in the tight junction to decrease paracellular phosphate 
permeability. Effects of pH on TEER have been previously reported (44). 
 
Tenapanor does not affect paracellular macromolecule absorption 
Both ions and small macromolecules can traverse cell monolayers via paracellular pathways, but 
it has been proposed that ions and macromolecules are absorbed via distinct pathways (45). 
 30 
 
Using radioactive tracers, the potential for tenapanor to affect paracellular macromolecule 
absorption was evaluated in vivo in rats and directly compared with its effect on phosphate ion 
absorption. Mannitol, a small (molecular weight 182) hydrophilic molecule thought to be 
exclusively absorbed via the paracellular route in vivo, was used as a marker of paracellular 
macromolecule absorption. Tenapanor significantly inhibited 33P absorption at both 0.5 mg/kg 
and 10 mg/kg (Fig. 8A) but had no effect on 3H-mannitol absorption (Fig. 8B). This suggests 
that tenapanor is selective for the paracellular ion absorption pathway over the macromolecule 
pathway. We also specifically tested the effect of tenapanor on intestinal glucose absorption, 
because NHE3 activity has previously been proposed to be coupled to paracellular glucose 
absorption (46). Unabsorbed glucose remaining in the luminal contents from the entire small 
intestine was measured at fixed time points following initiation of a standardized meal consumed 
over 4 hours in trained rats pretreated with tenapanor or vehicle. Dietary glucose was efficiently 
absorbed in the small intestine and this was unaffected by tenapanor treatment (Fig. 8C).  
 
 
Tenapanor reduces phosphate absorption in healthy human volunteers  
The effects of tenapanor on intestinal phosphate absorption were assessed in a phase 1 study 
conducted in healthy human volunteers. Participants received tenapanor 15 mg twice daily for 4 
days, and stool and urinary phosphorus excretion over this period were compared with baseline. 
Tenapanor treatment significantly (P < 0.05) increased mean daily stool phosphorus excretion 
from baseline (Fig. 8D), which was accompanied by a comparable and significant (P < 0.001) 
decrease in mean daily urinary phosphorus excretion (Fig. 8E). These results confirm that the 
ability of tenapanor to reduce gastrointestinal phosphate absorption in rats translates successfully 
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into humans. Tenapanor also significantly (P < 0.001) reduced mean daily urinary sodium 
excretion (Fig. 8F) but had no effect on urinary potassium excretion (Fig. 8G), consistent with 
its effects in rats. 
 
 
DISCUSSION 
 
Patients with CKD receiving dialysis develop complications due to mineral imbalances, such as 
hyperphosphatemia, that need to be managed effectively to improve health outcomes (9). Current 
medical management of hyperphosphatemia with dietary phosphate restriction and oral 
phosphate binders often proves inadequate to consistently achieve serum phosphate levels within 
the target range (22, 47-49). Additional strategies to optimize serum phosphate control are 
required, as hyperphosphatemia is associated with poor clinical outcomes (8-14). Management of 
elevated phosphate levels using dietary restrictions alone is generally inadequate, and current 
pharmacotherapy with oral phosphate binders is frequently poorly tolerated, involves an 
unacceptable pill burden (26, 51) and often provides insufficient efficacy (52, 53).  
 
Tenapanor is an investigational, small-molecule agent with a novel different mechanism of 
action from phosphate binders, and has the potential to address unmet needs in 
hyperphosphatemia therapy. Our investigations provide evidence for the mechanism by which 
tenapanor, an NHE3 inhibitor, reduces intestinal phosphate absorption. In vivo studies in rodents, 
combined with translational experiments conducted on human intestinal stem cell-derived 
enteroid monolayers to model intestinal ion transport physiology, indicate that the predominant 
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mechanism by which tenapanor produces its effect is the reduction of passive paracellular 
phosphate absorption, retaining activity even at high luminal phosphate concentrations.  
 
Our findings demonstrate that tenapanor decreases the paracellular absorption of phosphate by 
modulating tight junctions to increase TEER, thereby reducing paracellular phosphate 
permeability. Experiments using monolayers of NHE3 KO cells showed that the effect of 
tenapanor on TEER and paracellular phosphate permeability is mediated exclusively via on-
target inhibition of NHE3, and is likely the result of decreased pHi, a consequence of inhibition 
of proton secretion by NHE3. We have also shown that Tthe onset of action to increase TEER 
and reduce paracellular phosphate permeability is near immediate following NHE3 inhibition by 
tenapanor. Previous studies confirm that NHE3 inhibition or deletion is associated with increased 
TEER (46, 50, 51), although an effect on phosphate absorption has not previously been 
described.  However, rReduced urinary phosphate excretion has been reported in NHE3 KO 
mice (52), consistent with our finding of an NHE3-mediated reduction in intestinal phosphate 
absorption. 
 
Our studies have also shown that tenapanor is not a direct inhibitor of the most important active 
phosphate transporter, NaPi2b, although repeat administration of tenapanor in vivo does reduce 
the expression of NaPi2b at the transcriptional level and does not stimulate overall transcellular 
phosphate uptake. The contribution of reduced NaPi2b expression to the overall phosphate-
lowering effect of tenapanor is likely to be minor; however, it does indicate that tenapanor 
prevents increased active transcellular phosphate uptake from compensating for reduced 
paracellular phosphate absorption. The downregulation of NaPi2b produced by tenapanor is an 
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effect that further differentiates it from the commonly used phosphate binder sevelamer, which 
significantly increases NaPi2b expression in mice (34)In contrast, the commonly used phosphate 
binder sevelamer increases NaPi2b expression in mice (30), leading to enhanced transcellular 
phosphate absorption, which has been proposed to limit the phosphate-lowering efficacy of 
sevelamer (53).  
 
The effects of tenapanor on overall ion balance in preclinical models and in humans appear to be 
specific for sodium and phosphate. We have previously reported that tenapanor does not affect 
the overall balance of other ions in healthy humans and rats (23). In the current study, we show 
that tenapanor significantly reduced urinary phosphate excretion in humans, accompanied by 
increased stool phosphate, but had no effect on urinary potassium excretion. We previously 
reported that tenapanor had no effect on stool potassium excretion in healthy humans (23), 
confirming the lack of effect of tenapanor on intestinal potassium absorption, an ion reliant on 
paracellular absorption in the small intestine. We replicate this phenotype in rats and further 
show that tenapanor does not affect the urinary excretion of an additional anion, chloride. 
Enteropooling studies measuring luminal ion concentrations in rats confirm the preferential 
inhibition of phosphate absorption by tenapanor relative to chloride and potassium as well as the 
divalent cations, calcium and magnesium, which were unaffected by tenapanor. We have 
previously shown that urinary calcium excretion is unaffected by tenapanor in healthy humans, 
consistent with this result in rats (23). 
 
Although tight junction permeability can display some specificity towards individual or selected 
ion groups (34, 35), the in vivo phosphate preference was not readily reflected in direct 
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biophysical measurements of paracellular permeability, suggesting tight junction ion specificity 
is not the basis of tenapanor’s in vivo phenotypic selectivity. The reliance of phosphate on 
paracellular absorption likely explains the observed preferential effect of tenapanor on phosphate 
absorption. This is a consequence of the driving force for phosphate flux which itself is a result 
of a negative luminal potential applied to a divalent anion and low plasma phosphate 
concentrations relative to high luminal concentrations and the absence of a low-affinity, high-
capacity transcellular phosphate transporter. An examination of tenapanor’s effect on chloride, 
an anion presumably with similar inherent paracellular permeability characteristics to phosphate, 
highlights the in vivo specificity of tenapanor. Paracellular ion flux is an integrated outcome 
determined by paracellular permeability and the prevailing electrochemical gradient. Chloride 
permeability was reduced by tenapanor when measured by acutely imposing a nearly 100 mM 
chemical gradient to capture dilution potentials in Ussing chamber experiments ex vivo. 
However, measured luminal chloride concentrations in vivo were insufficient to support 
paracellular chloride absorption against normal plasma chloride concentrations, which are 
higher, indicating a prominent role of active transcellular chloride flux. Consequently, tenapanor 
had minimal overall impact on chloride such that 24-hour urinary chloride excretion was 
unchanged in the absence of a transcriptional response to upregulate chloride exchangers, 
transporters or channels. 
 
Further to the assessments of ion flux, tenapanor did not affect the absorption of mannitol tracer, 
indicating that tenapanor does not affect the paracellular macromolecule absorption pathway 
under physiological conditions in the small intestine. Moreover, tenapanor had no effect on 
intestinal glucose absorption. This indicates a low risk of inhibiting the paracellular absorption of 
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dietary macromolecules and a low risk of drug–drug interactions with the few agents absorbed 
by this pathway.  
 
A limitation of our study is that the method we used to follow pHi, using a pH-sensitive dye, 
only measured relative differences between interventions rather than an absolute quantification 
of pHi. This method was, however, sufficient to follow rapid dynamic pH changes that occurred 
following treatment with tenapanor and acidic apical media. These measurements are consistent 
with the ability of tenapanor to modulate tight junction phosphate permeability because of 
intracellular proton retention, resulting in a rapid decrease in pHi, as the effects of tenapanor on 
paracellular permeability were mimicked by luminal acidification and other interventions that 
reduce pHi. As pHi is tightly regulated within a narrow range to support normal cellular 
functions, it is likely that the magnitude of the effect of tenapanor on pHi is modest and probably 
locally confined to NHE3-expressing enterocytes. Importantly, we have previously reported in 
healthy volunteers that treatment with tenapanor does not affect serum bicarbonate or urinary 
pH, suggesting that systemic acid–base balance is not perturbed by this drug We demonstrated 
that the ability of tenapanor to modulate tight junction phosphate permeability is likely a result of 
intracellular proton retention resulting in a rapid decrease in pHi, as the effect of tenapanor on 
paracellular permeability as reflected by TEER could be mimicked by luminal acidification and 
other interventions that reduced pHi. Making direct measurements of dynamic, real-time pHi in 
intestinal monolayers cultured on Transwells and containing diverse cell types, some of which do 
not express NHE3, is technically challenging. A limitation of our study is that the method we 
used to follow pHi, using a pH sensitive dye, only provides a relative assessment of directional 
differences between interventions rather than an absolute quantification of pHi. This was 
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sufficient to follow the dynamic pH changes that occurred rapidly following treatment with 
tenapanor and acidic apical media, but does not provide an absolute value of pHi in the 
enterocyte. pHi is tightly regulated within a narrow range to support normal cellular functions, so 
it is likely that the magnitude of the effect of tenapanor on pHi is modest and probably locally 
confined to NHE3 expressing enterocytes. Additional mechanisms, including distinct NHE 
isoforms as well as bicarbonate transporters, can compensate for reduced NHE3 function at the 
level of the whole intestine thereby preventing systemic effects on acid–base parameters due to 
NHE3 inhibition. Indeed, we have previously reported in healthy volunteers that treatment with 
tenapanor does not affect serum bicarbonate or urinary pH, suggesting that systemic acid–base 
balance is not perturbed (23). 
 
A further limitation to these studies is our ignorance of the identity of the paracellular phosphate 
pore. The rapid, almost instantaneous increase in TEER with no obvious signaling pathway or 
tight junction protein trafficking suggests that a direct pH-sensitive conformational change to the 
tight junction may decrease paracellular phosphate permeability. For example, histidine residues 
on the intracellular termini of tight junction claudins could be direct pH sensors for the tight 
junction. Consistent with this possibility, a recently developed trans-tight junction patch clamp 
technique, applied to measure flux across an individual claudin channel, confirms that 
modulation of the gating kinetics of tight junction channels is an important mechanism of barrier 
regulation Our extensive investigations into the link between pHi and tight junction permeability 
failed to identify the involvement of a second messenger or signaling pathway. The rapid, almost 
instantaneous increase in TEER with no obvious signaling pathway or tight junction protein 
trafficking involved suggests the possibility that a direct pH-sensitive conformational change in 
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the tight junction might decrease paracellular phosphate permeability. For example, histidine 
residues found on the intracellular termini of tight junction claudins could be candidates for 
direct pH sensing by the tight junction. (54). Unfortunately, the molecular identity of the 
paracellular phosphate pore has not yet been elucidated, preventing characterization of the 
specific tight junction proteins involved. Further investigation of the structural and functional 
response of the tight junction to NHE3 inhibition is therefore required.  
To date, the molecular identity of the paracellular phosphate pore has not been elucidated, which 
prevents the characterization of the specific proteins involved. However, a novel trans-tight 
junction patch clamp technique, applied to measure flux across an individual claudin channel, 
has recently suggested that modulation of the gating kinetics of tight junction channels is indeed 
an important mechanism of barrier regulation (58). Further investigation of the structural and 
functional response of the tight junction to NHE3 inhibition is required to assess this, but beyond 
the scope of the current study. Connexins, a family of gap junction proteins that like claudins 
connect cells across the intercellular space, are pH-sensitive, providing a precedent for this 
possibility (59-62).  
 
Our results are most consistent with pHi mediating the effect of NHE3 inhibition on altered 
paracellular phosphate absorption. However, our work does not exclude a reduction in 
intracellular sodium (or resultant potential changes in osmolality and cell volume) or chloride, 
which may accompany NHE3 inhibition as a result of direct inhibition of transcellular sodium 
absorption or indirectly through inhibition of electroneutral sodium chloride absorption, being 
the possible mediators. Low intracellular sodium concentrations are established and maintained 
by the basolateral sodium/potassium (Na+/K+) ATPase and the resultant electrochemical sodium 
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gradient provides the driving force for secondary active intestinal transport of solutes coupled to 
luminal sodium absorption. The Na+/K+ ATPase likely adapts to reduced transcellular sodium 
influx via NHE3, such as is encountered in periods of fasting, to buffer variations in intracellular 
sodium and to prevent perturbations in cell osmolality and volume. However, the specific 
potential contributions of intracellular sodium or chloride concentrations should be the subject of 
future investigation.The ability of low apical pH to mimic the effect of tenapanor and the 
observation that other mechanisms that decrease pHi independent of NHE3 also increase TEER 
are most consistent with pHi coupling the effect of NHE3 inhibition to paracellular phosphate 
absorption. However, the potential involvement of reductions in intracellular sodium (or 
resultant potential changes in osmolality and cellular volume) or chloride that may accompany 
NHE3 inhibition as a result of direct inhibition of transcellular sodium absorption or indirectly 
through inhibition of electroneutral sodium chloride absorption have not been specifically tested 
in this series of experiments. Low intracellular sodium concentrations are established and 
maintained by the basolateral sodium/potassium (Na+/K+) ATPase and the resultant 
electrochemical sodium gradient is employed as the driving force for secondary active intestinal 
transport of solutes coupled to luminal sodium absorption. The Na+/K+ ATPase likely adapts to 
reduced transcellular sodium influx via NHE3, such as encountered in periods of fasting, to 
buffer variations in intracellular sodium concentrations and prevent perturbations in osmolality 
and cellular volume homeostasis. The specific potential contributions of intracellular sodium or 
chloride concentrations should be the subject of future investigation. 
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We have previously shown that tenapanor reduced urinary and serum phosphate in a rat model of 
CKD with vascular calcification (24) and here show that these effects on intestinal phosphate 
absorption translate to healthy humans. Tenapanor, a minimally absorbed, small-molecule 
inhibitor of NHE3 effectively increased stool phosphorus excretion and decreased urinary 
phosphorus excretion in humans when one 15 mg tablet was administered twice daily. Despite 
currently available treatments, many patients with ESRD fail to maintain target range serum 
phosphate concentrations (55, 56), with a key contributing factor being poor adherence to 
phosphate binder use as a result of the high required pill burden to effectively capture dietary 
phosphate (57). Oral phosphate binders act to bind phosphate directly in the gut lumen, forming 
non-absorbable complexes that are excreted in the feces and reducing the availability of dietary 
phosphate for absorption (65). To capture dietary phosphate effectively, however, binders need 
to be administered in multi-gram quantities, which results in a high pill burden. For patients 
receiving hemodialysis, phosphate binders can account for almost half of the total daily pill 
burden (26). Adherence to treatment is typically low and decreases with increasing pill counts, 
and the high pill burden can also adversely affect health-related quality of life (26). Tenapanor 
has potential to reduce the pill burden for these patients, and thereby improve treatment 
compliance. In addition, tenapanor remains effective in inhibiting intestinal phosphate absorption 
at high luminal phosphate concentrations. Tenapanor may therefore be the first agent that can 
effectively inhibit intestinal phosphate absorption in the setting of a liberalized phosphate diet. 
This could contribute an important significant nutritional benefit to patients with ESRD. 
  
In conclusion, tenapanor reduces intestinal phosphate absorption through the reduction of passive 
paracellular phosphate influx, quantitatively the most important overall mechanism of intestinal 
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phosphate absorption. Tenapanor modulates tight junctions to increase TEER and reduce 
paracellular permeability to phosphate; this effect is mediated exclusively via on-target inhibition 
of NHE3, and is likely the result of decreased pHi due to the inhibition of proton secretion. This 
novel mechanism of action means that Ttenapanor retains activity efficacy at high luminal 
phosphate concentrations and this translates to reduction of intestinal phosphate absorption in 
healthy humans. Evaluation of tenapanor in patients with ESRD and hyperphosphatemia is 
ongoing, to determine whether tenapanor provides offers a differentiated new approach to serum 
phosphate control in the clinical setting (58). 
 
 
 
MATERIALS AND METHODS 
 
Full details of materials and methods are included as Supplementary Material; an overview is 
provided here.  
 
Experimental Study design 
The primary objective of this work was to elucidate the mechanism by which tenapanor reduces 
intestinal phosphate absorption, which was explored using a combination of in vivo studies in 
healthy rodents and translational experiments on human intestinal stem cell-derived enteroid 
monolayers to model ion transport physiology. Intestinal phosphate absorption was assessed in 
vivo by measuring luminal and urinary phosphate concentration and excretion under various 
experimental conditions that manipulated the phosphate concentration gradient. Phosphate flux, 
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TEER and paracellular ion permeability were measured in human intestinal epithelial stem cell- 
derived enteroid monolayers under varying phosphate concentration gradients. The animal and 
cellular monolayer studies were controlled with vehicle control groups and assignment to 
treatment or control was randomized. Rigorous blinding of cellular and animal experiments with 
tenapanor was precluded due to obvious visual pharmacodynamic effects of tenapanor to prevent 
apical acid secretion in the monolayers and to alter fecal form in rodents; however, the analytical 
measurements for ion concentration were performed in a blinded manner. The translational effect 
of tenapanor on intestinal phosphate absorption was evaluated in a single-center, randomized, 
open-label study in 18 healthy human volunteers. 
The primary objective of this work was to elucidate the mechanism by which tenapanor reduces 
intestinal phosphate absorption, which was explored using a combination of in vivo studies in 
rodents and translational experiments on human intestinal stem cell-derived enteroid monolayers 
to model ion transport physiology. The effects of tenapanor on phosphate uptake seen in 
preclinical models were then evaluated in a clinical study in healthy volunteers. 
 
Animal studies 
Animal Use 
Animal experiments performed in the USA were conducted using experimental protocols 
approved by the Institutional Animal Care and Use Committee and performed in accordance 
with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
Experiments in the UK were performed in accordance with the UK Animals (Scientific 
Procedures) Act, 1986, Amendment Regulations 2012, using protocols approved by the 
University College London (Royal Free Campus) Comparative Biology Unit Animal Welfare 
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and Ethical Review Body (AWERB) Committee. Experiments in Sweden were approved by The 
Regional Animal Ethics Committee for Experimental Animals, University of Gothenburg. 
 
In vivo loop model 
In anesthetized male Sprague Dawley (SD) rats, a 5 cm segment of jejunum was cannulated and 
flushed with warm 0.9% saline, then air. Uptake buffer containing 33PO4
3− plus tenapanor 
(10 µM) or vehicle control was instilled in the lumen and the segment tied off. Scintillation 
counting of plasma and initial uptake solution was used to calculate phosphate transfer from the 
lumen into the blood. The procedure was also performed in ileum loops of intestinal-specific 
NaPi2b KO mice (28) and wild-type littermates. 
 
In vivo oral phosphate bolus 
After overnight fast, male SD rats were dosed orally with tenapanor (0.5 mg/kg) or vehicle, and 
1 mL of NaH2PO4 solution (0.15, 0.5 or 1.5 M) or water control, and immediately placed in 
individual metabolic cages for 4 hours. Urinary sodium and phosphate concentration, measured 
by ion chromatography, and urine volume were used to calculate 4-hour urinary sodium and 
phosphate excretion. 
 
Changes in dietary phosphorus intake 
Male SD rats, fed diets containing 0.3%, 0.6% or 1.2% phosphorus (TD.85010, TD.84122, 
TD.85349 respectively, Envigo, Maddison, WI), were individually housed in metabolic cages. A 
24-hour urine collection was performed at baseline and following twice-daily oral treatment with 
tenapanor (0.5 mg/kg) or vehicle, for 4 days. Urinary sodium and phosphate concentration, 
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measured by ion chromatography, and urine volume were used to calculate 24-hour urinary 
sodium and phosphate excretion. 
 
Enteropooling studies to measure luminal ion content 
Male SD rats fed a 0.6% phosphorus diet for 6 days were dosed orally with tenapanor 
(0.15 mg/kg) or vehicle immediately before a final 5 g meal containing 1.2% phosphorus 
(TD.85349). In one cohort of animals, 4-hour urine collection was performed to determine 
urinary sodium and phosphate excretion. In a separate cohort, animals were euthanized at 0.5, 1 
and 2 hours following dosing, and the contents of the cecum were collected for ion 
chromatography. 
 
Effects of long-term administration of tenapanor on phosphate and sodium in vivo 
Male SD rats fed a diet containing 0.6% phosphorus (TD.84122), were dosed orally with 
tenapanor (0.5 mg/kg) or vehicle twice daily for 14 days. Daily 24-hour urinary collections were 
made to measure urinary sodium and phosphate excretion. On the final study day, plasma was 
collected for measurement of sodium, phosphate, FGF-23 (C-terminal and intact), intact 
parathyroid hormone and vitamin D. Renal sodium and phosphate clearance and fractional 
excretion were calculated using standard methods. RNA was isolated from various 
gastrointestinal segments and NaPi2b mRNA expression was measured by qPCR.  
 
Radioactive mannitol and phosphate absorption 
Male SD rats were surgically implanted with a jugular vein catheter, recovered (1 week), fasted 
overnight and then dosed orally with tenapanor or vehicle along with 33P- or 3H-mannitol tracer 
 44 
 
and blood samples were collected at multiple time points through 120 minutes. Plasma 
radioactivity was measured by liquid scintillation. 
 
Immunohistochemistry in rat jejunum after in vivo treatment with tenapanor 
Tissues were fixed in 4% neutral buffered formaldehyde and paraffin-embedded. The primary 
antibody AGGSY87 (AGG) diluted 1:1500 (0.4 µg/mL) in Da Vinci Green (Biocare medical, 
PD900M) was incubated for 1 hour followed by use of a Rabbit on Rodent Polymer kit 
(RMR622, Biocare Medical).  
 
Intestinal epithelial stem cell monolayer culture model 
Intestinal epithelial stem cell monolayers were cultured and differentiated on Transwells as 
described in detail by Kozuka et al. (38). Human biopsies from which stem cells were sourced 
were obtained according to a protocol approved by the Copernicus Group Institutional Review 
Board (Durham, NC, USA). 
 
Experiments were initiated in each differentiated monolayer culture well by washing the apical 
and basolateral side twice with fresh supplemented basal media and phosphate-free Dulbecco’s 
modified Eagle medium. Compounds were dosed only on the apical side of the monolayer, as 
detailed in the text; DMSO at an equivalent concentration was used as the control. Phosphate 
concentration and pH were manipulated as described in the text. Apical and basolateral ion 
concentrations were measured by ion chromatography, pH was measured using a pH meter, and 
TEER values were recorded using a Volt/Ohm meter. TEER results are reported as normalized to 
baseline levels. Absolute baseline TEER values are reported in Supplementary Table S1. 
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pHi recovery (NHE3 activity assay) 
Stem cell-derived human intestine organoid monolayers were incubated with 10 µM pH-
sensitive BCECF-AM dye for 1 hour in sodium-free buffer, then the dye was aspirated and the 
cells washed with sodium-free buffer. Sodium-containing buffer at different pH values levels 
was added to the apical compartment, in the presence and absence of tenapanor, while 
monitoring the intracellular BCECF signal using a fluorescent imaging plate reader (FLIPR). 
NHE3 activity was calculated by measuring the initial rate of change of fluorescence from the 
time of buffer addition to 180 seconds. It is important to note that in our experiments only 
relative, not absolute, changes in pH were measured. 
 
pHi endpoint assay 
Human organoid stem cell monolayers were incubated with 10 µM pH-sensitive BCECF-AM 
dye for 30 minutes in sodium-containing buffer, then the dye was aspirated and the cells washed 
with sodium-containing buffer. Tenapanor or DMSO control were added to the apical 
compartment, and fluorescence readings were acquired every 5 minutes for 30 minutes. The pH 
level was calculated from the ratio of the two fluorescent excitation wavelengths. The effects of 
nigericin, FCCP and BAM15 on pHi were also determined 30 minutes after application using the 
same method. Over the 30-minute period of intracellular BCECF intensity measurements, plates 
were kept at 37°C in ambient CO2. 
 
Biophysical assessment of paracellular permeability using dilution and biionic diffusion 
potential measurements 
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To assess the effect of tenapanor on paracellular ion permeabilities we performed paired 
experiments in Ussing chambers on human duodenum monolayer cultures and mouse jejunum 
tissue ex vivo. We first measured a sodium chloride (NaCl) dilution potential followed by a 
phosphate biionic dilution potential, and then we repeated these measurements on the same 
samples but in the presence of tenapanor or vehicle control. Similar methods have been 
described previously (59). NaCl dilution potentials were induced by changing the apical chamber 
from a Krebs Ringers solution to a low sodium chloride (55 mM) solution otherwise identical to 
Krebs Ringers with osmolality balanced with mannitol. Phosphate chloride biionic diffusion 
potentials were generated by replacing the apical solution with modified Krebs Ringers where 
Na2HPO4 replaced most of the NaCl. Osmolality was balanced with mannitol. The pH of each 
solution was titrated to 8.0 with 1 M sodium hydroxide, to ensure a favorable proton gradient for 
NHE3 mediated transport and to simplify permeability calculations by restricting the phosphate 
to the HPO4
2− species.  
 
Immunofluorescence and 3D confocal imaging of cultured cells 
Differentiated human ileum cells in Transwell plates were treated with tenapanor (1 µM) or 
DMSO on the apical side. For endocytosis inhibitor treatment, cells were pre-treated with 
pitstop2 or dynasore for 30 minutes, then carbachol (10 µM) was added and the cells incubated 
for 30 minutes. Nuclei were detected by DAPI (4',6-diamidino-2-phenylindole) staining; the 
apical membrane and F-actin filaments were stained by adding WGA Alexa Fluor 488 conjugate 
and phalloidin dye, respectively, to the apical side. After staining, the membrane was cut out and 
mounted, and cells visualized by confocal microscopy.  
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CRISPR/Cas9-mediated NHE3 gene editing 
Gene editing was performed using lentiviral Cas9 and single guide RNA (sgRNA) particles. For 
the initial transduction, organoids (broken into single cells) were mixed with Edit-R lentiviral 
mCMV-Blast-Cas9 nuclease particles, and transduced cells were selected with blasticidin. At 2–
3 weeks post-transduction, cells with stable Cas9 overexpression were further transduced with 
Edit-R human lentiviral SLC9A3 sgRNAs or non-targeting control #1 sgRNA particles, and 
selected with puromycin. For clonal expansion of NHE3 KOs and non-targeting controls, single 
organoids were picked and expanded in growth medium for 2 weeks in the presence of 
antibiotics. Transduced cells were genotyped using PCR on isolated genomic DNA; protein 
expression in transduced cells was assessed using immunoblot analysis.  
 
Brush Border Membrane Vesicle (BBMV) isolation and phosphate transport  
BBMVs were prepared by the Mg2+-precipitation technique (60-62) from mucosal cells scraped 
from the individual segments of inverted small intestine. Final membranes were resuspended at a 
concentration of 1–15 mg total protein, determined according to Bradford (63). The transport 
rates of 32P and 3H-D-glucose into BBMVs were measured as described (64) at 25°C in the 
presence of inwardly directed gradients of 100 mM NaCl or 100 mM KCl and 0.1 mM potassium 
phosphate or 0.1 mM D-glucose. Uptakes were measured after 90 seconds and 90 minutes to 
determine equilibrium values.  
 
Tenapanor in healthy volunteers 
Healthy male and female volunteers (aged 19–65 years; BMI 18–29.9 kg/m2) were enrolled in a 
single-center, randomized, open-label, three-way crossover study to evaluate different tenapanor 
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formulations (ClinicalTrials.gov identifier: NCT02249936). The study protocol was approved by 
the IntegReview Institutional Review Board (Austin, TX, USA). All participants provided 
written informed consent and the study was conducted in accordance with the Declaration of 
Helsinki, and International Conference on Harmonisation and Good Clinical Practice guidelines. 
Volunteers received a different one of the three tenapanor formulations in each treatment period 
(days 1–4, 7–10 and 13–16), according to the randomization scheme. Tenapanor was 
administered twice daily before a standardized meal, and 24-hour urine and stool collections 
were made daily throughout the study period (day –2 to day 17). Data are presented for the 
tenapanor HCl tablet formulation.  
 
Statistical Analysis 
The data analyzed were continuous, quantitative and normally distributed, as assessed by 
D'Agostino-Pearson omnibus normality test. Between-group differences over time were assessed 
by a two-way mixed-design analysis of variance (ANOVA), and post hoc testing at each time 
point was performed using Bonferroni’s procedure to correct for multiple comparisons 
(GraphPad Prism 6). Between-group differences (≥ 3-groups) with only one time point were 
assessed by one-way ANOVA and post hoc multiple comparisons with Dunnet’s test. Pair-wise 
comparisons were made by Student’s t-test. P < 0.05 was considered significant. All results are 
presented as mean ± standard error, except the clinical study (Fig. 8D–G) for which results are 
mean ± standard deviation. 
 
LIST OF SUPPLEMENTARY MATERIALS 
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Supplementary Materials and Methods 
Fig. S1. NHE3 is endogenously, highly expressed at high levels in enteroid monolayer cultures 
from different segments of the human and mouse intestine and is potently and completely 
inhibited by tenapanor. 
Fig. S2. Tenapanor inhibits phosphate absorption across a range of initial apical phosphate 
concentrations in human ileum monolayer cultures. 
Fig. S3. NHE3-independent changes in pHi modulate trans-epithelial electrical resistance in 
intestinal ileum monolayer cultures. 
Fig. S4. Paracellular phosphate absorption in NHE3 knockout human duodenum monolayer 
cultures. 
Fig. S5. Renal and hormonal responses to chronic in vivo tenapanor treatment in healthy rats. 
Fig. S6. Tenapanor has little effect on phosphate uptake predominantly mediated by NaPi2b or 
sodium-dependent glucose uptake in rat duodenum or jejunum brush border membrane vesicles. 
Fig. S7. Tenapanor does not affect the localization of tight junction specific proteins in human 
ileum and tenapanor-induced increases in TEER are not affected by blocking endocytosis. 
Table S1. Absolute TEER (Ohm.cm2) at baseline for all experimental conditions prior to the 
experimental intervention.  
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FIGURE LEGENDS 
 
Fig. 1. Effects of tenapanor on phosphate absorption in vivo in rats.  
(A) Effect on radioactive phosphate absorption of tenapanor (10 µM) and of a sodium-free buffer 
(ChCl plus PFA) in the rat jejunum in vivo loop model with initial luminal phosphate 
concentration of 8 mM; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs vehicle 
(n = 5–7 per group). (B) Urinary phosphate excretion 4 hours after an oral bolus of varying 
phosphate concentrations (0.15–1.5M) with or without tenapanor (0.5 mg/kg) in vivo in rats; 
*P < 0.05, **P < 0.01, ****P < 0.0001 vs vehicle (n = 6 per group). (C) Urinary phosphate 
excretion at different dietary phosphate levels intake at baseline and after 4 days of treatment 
with tenapanor (0.5 mg/kg) or vehicle in vivo in rats; ***P < 0.001, ****P < 0.0001 (n = 7 per 
group). (D) Urinary phosphate and urinary sodium excretion 4 hours after a fixed quantity (5 g) 
of high phosphorus (1.2%) meal in rats treated with tenapanor (0.15 mg/kg) or vehicle; 
****P < 0.0001 vs vehicle (n = 8 per group). Cecal (E) sodium delivery, (F) phosphate delivery, 
(G) water volume, (H) sodium concentration, (I) phosphate concentration, (J) potassium 
concentration, (K) chloride concentration, (L) calcium concentration, and (M) magnesium 
concentration in rats fed a fixed quantity of high phosphorus (1.2%) meal and treated with 
vehicle or tenapanor (0.15 mg/kg); *P < 0.05, **P < 0.01, ****P < 0.0001 (n = 6 per time point 
per group).  
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Fig. 2. Effects of phosphate concentration gradient and tenapanor on phosphate absorption 
in human duodenum monolayer cultures. 
(A) Correlation between phosphate flux and initial apical phosphate concentration in human 
duodenum monolayer cultures from two separate donors, A and B, and the reproducibility of 
phosphate absorption in donor B in experiments from two separate passages (n = 4 per group) 
following overnight incubation. (B) Basolateral phosphate concentration, (C) phosphate flux, 
and (D) trans-epithelial electrical resistance (TEER) at different apical phosphate concentrations 
(1–30 mM) in human duodenum monolayer cultures following 4 hours of treatment with 
tenapanor (1 µM) or vehicle with an initial starting basolateral phosphate concentration of 0 mM; 
*P < 0.05, ****P < 0.0001 vs vehicle (n = 4–16 per group). (E) Apical phosphate retention, (F) 
apical phosphate concentration, (G) basolateral phosphate concentration, and (H) apical fluid 
volume at different initial apical phosphate concentrations (1–30 mM) in human duodenum 
monolayer cultures following overnight treatment with tenapanor (1 µM) or vehicle with an 
initial starting basolateral phosphate concentration of 1 mM; data from donor B. (I) Effect of 
tenapanor (1 µM) or vehicle on bidirectional phosphate flux at varying phosphate concentration 
gradients (1–10 mM) in human duodenum monolayer cultures; *P < 0.05, ***P < 0.001, ****P 
< 0.0001 vs vehicle (n = 4 per group). 
 
 
  
 63 
 
Fig. 3. Trans-epithelial electrical resistance and pHi in human intestinal cell monolayer 
cultures. 
Effects of tenapanor (1 µM) versus control on trans-epithelial electrical resistance (TEER) 
following the change from old acidic (pH 6.0) apical media at baseline to fresh neutral pH apical 
media to restore the gradient for NHE3-mediated proton efflux in (A) human duodenum and (B) 
human ileum cell monolayer cultures; **P < 0.01, ****P < 0.0001 vs control (n = 3 per group). 
(C) TEER following the change from old acidic (pH 6.0) apical media at baseline to fresh apical 
media at different (acidic to alkaline) pH in human duodenum monolayer cultures (n = 3 per 
group). (D) Effect of tenapanor (1 µM) on TEER at varying apical media pH in human 
duodenum monolayer cultures normalized to equivalent pH level treated with vehicle (n = 3 per 
group). Recovery of pHi, initiated by the addition of a sodium-containing media and measured 
using pH-sensitive BCECF-AM dye following acid loading in sodium-free media in (E) human 
duodenum and (F) human ileum monolayer cells at different apical pH in the presence of 
tenapanor (1 µM) or vehicle. (G) Concentration–response effect of tenapanor on rate of the 
recovery from intracellular acidification at neutral and acidic apical pH in human ileum 
monolayer cultures. (H) Change in pHi, measured using BCECF-AM dye, over time following 
the change to acidic, neutral or alkaline pH apical media in human ileum monolayer cultures; 
***P < 0.001, ****P < 0.0001 vs pH 6.0. Effect of tenapanor (1 µM) (vs control) on change in 
(I) pHi and (J) TEER over time in human ileum monolayer cultures; *P < 0.05, **P < 0.01, 
***P < 0.001 vs control (n = 3–6 per group).  
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Fig. 4. Effect of apical pH on phosphate flux and effect of tenapanor on phosphate flux at 
different apical pH levels.  
Effect of varying apical pH levels on basolateral phosphate flux in human ileum epithelial cell 
monolayer cultures following an overnight incubation at an initial apical phosphate concentration 
of 10 mM or 30 mM and an initial basolateral phosphate concentration of 0 mM, in the absence 
(A) and presence (B) of tenapanor (1 µM); the effect of tenapanor is represented as change from 
vehicle. (C) Phosphate flux, measured with radioactive tracer and (D) paracellular phosphate 
permeability (pPO4
3−), measured by biionic dilution potential in mouse jejunum strips at pH 6.0 
and pH 8.0. *P <0 .05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs control (n = 4–6 per 
group).  
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Fig. 5. Effect of tenapanor on paracellular permeability measured by direct biophysical 
methods, and the chemical driving forces for paracellular absorption in vivo in rats. 
Effect of tenapanor at pH 8.0 on (A) TEER, (B) sodium permeability, pNa+, (C) chloride 
permeability, pCl-, (D) sodium-to-chloride permeability, pNa+/pCl- and (E) phosphate 
permeability, pPO4
3− in human duodenum monolayer cultures mounted in Ussing chambers. 
Effect of tenapanor on (F) TEER, (G) pNa+, (H) pCl-, (I) pNa+/pCl- and (J) pPO4
3− across mouse 
jejunum ex vivo mounted in Ussing chambers. Luminal concentrations of (K) sodium, (L) 
chloride and (M) phosphate in the proximal and distal small intestine in untreated rats trained to 
eat a standardized meal. *P < 0.05 vs control (n = 6 per group). 
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Fig. 6. Paracellular phosphate absorption in NHE3 knockout human ileum monolayer 
cultures. 
(A) DNA sequencing showing CRISPR/Cas9-mediated gene editing of NHE3 resulting in 
nucleotide deletions and insertions. The sgRNA targeting human NHE3 genomic DNA exon 2 
(sgNHE3-13) is shown in red and the protospacer adjacent motif (PAM) region in blue. The 
NHE3 knockout line (sgNHE3-13 clone 45) contains two different types of mutations (Mut 1 and 
Mut 2), shown in grey boxes. (B) Western blot showing NHE3 and beta-actin (ACTB) protein 
expression in control and NHE3 edited cells, (C) apical media showing acidification (yellow) or 
absence of acidification (pink) in control and NHE3 edited cells. Recovery from intracellular 
acidification following acid loading in the absence or presence of tenapanor in (D) control (non-
targeting sgControl clone 4) and (E) NHE3 knockout (sgNHE3-13 clone 45) human ileum 
epithelial cell clones. (F) Apical volume, (G) apical sodium, (H) apical phosphate and (I) apical 
pH in control and NHE3 knockout human ileum monolayers following overnight incubation; 
**P < 0.01, ****P < 0.0001 vs control (n = 6 per group). (J) TEER following the change from 
old acidic (pH 6.0) apical media at baseline to fresh neutral pH apical media to restore the 
gradient for NHE3 mediated proton efflux in control and NHE3 knockout monolayers; ****P < 
0.0001 vs control (n = 4 per group). (K) Change in apical-to-basolateral phosphate absorption 
and (L) change in apical phosphate concentration with tenapanor (1 µM), normalized to the 
effect of vehicle in NHE3 knockout and control monolayers; *P < 0.05, ***P < 0.001 vs vehicle 
(n = 4 per group). (M) Change in TEER with tenapanor relative to vehicle following the change 
to neutral pH apical media in control and NHE3 knockout monolayers; ****P < 0.0001 vs 
control (n = 4 per group). 
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Fig. 7. Effects of tenapanor on NaPi2b mRNA and protein expression in vivo in rats, the 
effects of tenapanor and a NaPi2b inhibitor on phosphate absorption in mouse ileum 
monolayer cultures, and the effects of tenapanor on phosphate absorption in the in vivo 
loop model in the ileum of wild-type and NaPi2b knockout mice.  
(A) NaPi2b mRNA expression in different intestinal segments following 14 days of tenapanor 
(0.5 mg/kg) or vehicle treatment in rats; **P < 0.01, ****P < 0.0001 vs vehicle (n = 8 per 
group). (B) Immunohistochemistry showing NaPi2b expression in rat jejunum following in vivo 
treatment with tenapanor or vehicle. (C) Apical and basolateral phosphate concentrations 
following overnight incubation at different initial apical phosphate concentrations (1–5 mM) in 
mouse ileum monolayer cultures with initial basolateral phosphate concentration of 1 mM; 
****P < 0.0001 (n = 6 per group). (D) Apical phosphate concentrations following a 4-hour, 2-
day or 3-day incubation with tenapanor (1 µM), NTX-9066 (a NaPi2b inhibitor; 1 µM) or 
vehicle in mouse ileum monolayer cultures; ****P < 0.0001vs initial apical phosphate 
concentration (1 mM). Initial basolateral phosphate concentration was set at 1 mM, so there was 
no phosphate concentration gradient for passive diffusion (n = 6 per group). (E) Phosphate 
absorption with tenapanor (10 µM) versus vehicle in NaPi2b knockout (KO) and control (wild-
type) mouse ileum in an in vivo ileum loop model; ***P < 0.001 (vehicle-treated wild-type vs 
NaPi2b KO) (n = 4–5 per group). 
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Fig. 8. Effects of tenapanor on paracellular macromolecule absorption compared with 
phosphate absorption in rats, and on phosphate, sodium and potassium absorption in 
healthy human volunteers. 
(A) Radioactive phosphate and (B) radioactive mannitol absorption in vivo in rats following 
treatment with different doses of tenapanor. (C) Small intestinal glucose content following 
initiation of a standardized meal in rats pretreated with vehicle or tenapanor; *P < 0.05, **P < 
0.01, ****P < 0.0001 vs vehicle (n = 4–7 per group). (D) Stool and (E) urinary phosphorus, (F) 
urinary sodium and (G) urinary potassium excretion at baseline and after 4 days of tenapanor 
treatment (15 mg b.i.d.) in healthy volunteers participating in a formulation study; *P < 0.05, 
***P < 0.001, ****P < 0.0001 vs day −1.  
 
 
